LEADER 01723nam  2200421Ia 450 
001 9910695979303321
005 20070716160029.0
035   $a(CKB)5470000002374005
035   $a(OCoLC)155854244
035   $a(EXLCZ)995470000002374005
100   $a20070716d2007      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aDrug safety$b[electronic resource] $efurther actions needed to improve FDA's postmarket decision-making process : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives /$fstatement of Marcia Crosse
210  1$a[Washington, D.C.] :$cU.S. Govt. Accountability Office,$d[2007]
215   $a13 pages $cdigital, PDF file
225 1 $aTestimony ;$vGAO-07-856 T
300   $aTitle from title screen (viewed on July 3, 2007).
300   $a"For release ... May 9, 2007."
300   $aPaper version available from: U.S. Govt. Accountability Office, 441 G St., NW, Rm. LM, Washington, D.C. 20548.
320   $aIncludes bibliographical references.
517   $aDrug safety 
606   $aDrugs$xSafety measures
606   $aDrugs$xSafety measures$xGovernment policy$zUnited States
615  0$aDrugs$xSafety measures.
615  0$aDrugs$xSafety measures$xGovernment policy
700   $aCrosse$b Marcia$01380679
712 02$aUnited States.$bCongress.$bHouse.$bCommittee on Energy and Commerce.$bSubcommittee on Health.
712 02$aUnited States.$bGovernment Accountability Office.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910695979303321
996   $aDrug safety$93449630
997   $aUNINA